Today: 9 June 2026
Browse Category

Stock Market 5 June 2026

QQQ Drops After Surprise Jobs Data, Market Eyes Rates and AI

QQQ Drops After Surprise Jobs Data, Market Eyes Rates and AI

Invesco QQQ Trust plunged 3.29% to $716.26 after a strong U.S. jobs report boosted rate-hike odds to 70%, hitting tech and AI stocks that dominate the ETF; the drop pushed QQQ below key technical support, with investors now weighing near-term rate risk over long-term growth, as higher yields threaten future earnings valuations.
5 June 2026
······
IREN Stock Down Despite 800MW AI Data Center Deal

IREN Stock Down Despite 800MW AI Data Center Deal

IREN shares plunged 13.9% to $53.29 after announcing an 800MW South Australia data-center campus and closing a $3.65 billion GPU financing facility, as investors sold AI and crypto-linked stocks amid a sharp Nasdaq selloff and falling bitcoin prices; B. Riley raised its price target to $96 but cut near-term EBITDA estimates.
5 June 2026
··
Vanguard Growth ETF’s Low Fees Draw Focus as AI Surge Faces Scrutiny

Vanguard Growth ETF’s Low Fees Draw Focus as AI Surge Faces Scrutiny

Vanguard Growth ETF plunged 2.7% to $86.79 Friday as a tech-led selloff hit top holdings like Nvidia, Apple, and Microsoft, despite a 27.64% one-year gain and ultra-low 0.03% fee; the drop followed a strong U.S. jobs report that pushed rate-hike bets higher and triggered a sharp reversal in growth and chip stocks.
5 June 2026
········
Planet Labs Drops After $1.5 Billion Filing

Planet Labs Drops After $1.5 Billion Filing

Planet Labs plunged 22% to $33.86 after announcing a $1.5 billion at-the-market share-sale program, sparking dilution fears despite record Q1 revenue up 42% to $94.2 million and raised full-year guidance; analysts remain split, with Needham upping its price target to $53, while the average target sits below the current price even after the drop.
5 June 2026
··
AI-driven stocks stall on Wall Street after jobs report shakes chip sector

AI-driven stocks stall on Wall Street after jobs report shakes chip sector

Chip stocks plunged Friday, with Broadcom down 4.5% and Nvidia 3.7%, after a stronger-than-expected May jobs report fueled fears the Fed may delay or reverse rate cuts, slamming AI-linked shares that powered this year’s rally; Broadcom’s revenue and AI chip forecast missed Wall Street estimates, triggering a 4.7% drop in the semiconductor ETF as investors demanded perfection.
5 June 2026
····
Nokia Shares Slide as €500 Million Debt Deal Hits AI Rally

Nokia Shares Slide as €500 Million Debt Deal Hits AI Rally

Nokia shares slid 3.27% in Helsinki and 5.96% in New York as the company issued €500 million in new debt to refinance existing notes, cooling a recent AI-driven rally and highlighting investor jitters over whether rising AI and cloud demand can sustain the stock’s recent surge ahead of next month’s earnings report.
5 June 2026
·
1 … 9 10 11 12 13 … 1,533

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Go toTop